Why is Brilinta Preferred Over Plavix? A Pharmacological Analysis
•
4 min read
In the landmark PLATO trial, ticagrelor (Brilinta) demonstrated superior efficacy over clopidogrel (Plavix) in reducing the rate of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS). This pivotal finding, along with critical differences in mechanism and metabolism, helps explain why Brilinta is preferred over Plavix in many clinical scenarios.
